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Abstract. Piroxicam is an anti-inflammatory drug of the NSAID class that is commonly 
used as an analgesic and anthireumatic drug. Its use is often combined with gastric drugs, 
one of which is omeprazole, considering the side effects of piroxicam which can irritate the 
stomach. Piroxicam and omeprazole work on the same enzyme, CYP-450 so that it can 
affect the pharmacokinetic profile especially in the metabolic and excretion phases of 
piroxicam. This research is an experimental study using 3 male rabbits. Measurement of 
plasma levels of piroxicam drug is carried out using a High Performance’s Liquid 
Chromatography (HPLC) tool. The validation method is used to determine LOD and LOQ 
values, accuracy, and precision tests. The results of data analysis using t-tables. The results 
showed the value of pharmacokinetic parameters in the absorption phase increased or there 
were differences but did not show any significant effect on each group. While the 
pharmacokinetic parameter values in the metabolic and excretion phases decreased and 
showed no differences between groups. The administration of omeprazole and piroxicam 
together and the administration of piroxicam which was given an hour earlier by 
omeprazole can inhibit the enzyme that stimulates the metabolism of piroxicam so that it 
affects the pharmacokinetic parameters in the absorption phase and also excretion but is not 
significant. 
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Abstrak. Piroxicam adalah obat antiinflamasi golongan NSAID yang biasa digunakan 
sebagai obat analgesik dan antirematik. Penggunaannya sering dikombinasi dengan obat 
lambung salah satunya omeprazole mengingat efek samping dari piroxicam yaitu dapat 
mengiritasi lambung. Piroxicam dan omeprazole bekerja pada enzim yang sama yaitu 
CYP-450 sehingga dapat mempengaruhi profil farmakokinetika terutama pada fase 
metabolisme dan eksresi piroxicam.Tujuan penelitian ini untuk mengetahui pengaruh 
pemberian omeprazole terhadap profil farmakokinetika piroxicam terutama pada fase 
metabolisme dan eksresi. Penelitian ini adalah penelitian eksperimental menggunakan 3 
ekor kelinci jantan. Pengukuran kadar obat piroxicam dalam plasma dilakukan dengan 
menggunakan alat Kromatografi Cair Kinerja Tinggi (KCKT). Dilakukan metode validasi 
yaitu penentuan nilai LOD dan LOQ, uji akurasi dan uji presisi. Hasil analisis data 
menggunakan t tabel.Hasil penelitian menunjukkan nilai parameter farmakokinetika pada 
fase absorpsi mengalami peningkatan atau terdapat perbedaan namun tidak menunjukkan 
adanya pengaruh yang berarti pada masing-masing kelompok. Sementara nilai parameter 
farmakokinetika pada fase metabolisme dan eksresi mengalami penurunan dan 
menunjukkan adanya perbedaan antara kelompok tidak signifikan. Pemberian omeprazole 
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dan piroxicam secara bersamaan dan pemberian piroxicam yang satu jam sebelumnya 
telah diberikan omeprazole dapat menginhibisi enzim pemetabolisme piroxicam sehingga 
mempengaruhi parameter farmakokinetika pada fase absorbs dan juga eksresi namun tidak 
signifikan. 
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1. Introduction 
The use of drugs for more than one active substance (polypharmacy) in the treatment of disease 
is often found in a patient. The complexity of the drugs used allows drug interactions, where a 
substance influences drug activity, for example the effect of increasing or decreasing or 
producing new effects that are not produced by the drug itself. This interaction needs to be 
considered because it affects the body's response to treatment [1,2,3]. A drug interaction occurs 
when a patient’s response to a drug is modified by food, nutritional supplements, formulation 
excipients, environmental factors, other drugs or disease. Interactions between drugs may be 
beneficial or harmful [4]. Drug interactions can provide changes to drug activity, either by 
increasing toxic effects or decreasing therapeutic effects [5].In addition, some drug interactions 
can also support each other's work or the opposite of drug interactions can result in the action of 
one drug inhibited by other drugs [6]. 
 
One mechanism of drug interactions that occur in the body is pharmacokinetic interactions that 
occur when one drug can affect the absorption, distribution and elimination (metabolism and 
excretion) of other drugs, so that the level of the affected drug will increase or decrease [2]. 
Interactions in metabolic processes are the most common cases, where about 50 - 60% of the 
drugs used in therapy can interact with each other on the same enzyme[7]. Piroxicam is a drug 
that has analgesic, antirheumatic and anti-inflammatory activity which is more or less the same 
as indomethacin, a relatively long work period with a dose of 10-20 mg daily. Piroxicam is well 
absorbed in the digestive tract, 99% of the drug is bound by plasma protein [8]. Piroxicam is 
often combined with gastrointestinal medication given the side effect of piroxicam is that it can 
irritate the stomach. And in this study, the stomach medicine used is omeprazole, which is one 
drug that is widely used in the community. This study was conducted with the aim of finding 
out whether or not there was an influence on the administration of omeprazole on the 
pharmacokinetic profile of piroxicam, especially in the metabolic phase and also in the 
excretion phase. 
2.   Materials and Methods 
This research was an experimental research. The tools used in this study were a complete HPLC 
unit (Shimadzu), politube, beaker glass, vortex, waterbath, centrifuge, pumpkin, pH meter, 
PTFE membrane filter 0.5 μm, measuring cup, analytical balance (Boeco Germany ), volume 
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pipettes, drop pipettes, gloves, syringes (Terumo), oral sonde, stopwatch, rabbit cages, masks, 
animal scales. The materials used in this research were standard piroxicam (PT. Brataco), 
piroxicam and omeprazole tablets, sodium CMC, aquabidest, methanol PA (E.Merck), TCA, 
heparin, distilled water. 
2.1. Preparation of Suspension  
The preparation of suspension carried out in this study was the manufacture of 0.5% Sodium 
CMC suspense using 2.5 g CMC Na sprinkled evenly into a mortar containing 100 ml of hot 
distilled water. Allowed to stand for 30 minutes to obtain a transparent mass, then diluted with 
500 mL of distilled water. Then preparation of suspension, piroxicam weighed as much as 10 
mg gently crushed in a mortar, add 50 ml of 0.5% CMC Na suspension homogenized, then 
transferred to a 100 ml volumetric flask, then added 0.5% CMC Na until it was reached the 
mark limit. Preparation of Omepraole suspension, Omeprazole weighed as much as 20 mg 
gently crushed in mortars, added 50 ml of 0.5% CMC Na suspension homogenized then 
transferred into a 100 ml volumetric flask, then added 0.5% CMC Na to the marking limit [9]. 
2.2. Tests on the pharmacokinetics profile 
The testing of pharmacokinetic profiles was carried out with 3 treatments. The first treatment 
was the treatment in experimental animals by administering piroxicam at a dose of 0.653 
mg/kgbw without omeprazole administration. The second treatment was the treatment in 
experimental animals by administering piroxicam at a dose of 0.606 mg/kgbw which 1 hour 
earlier was given omeprazole at a dose of 1.2 mg/kgbw. The third treatment, namely the 
treatment of experimental animals by administering piroxicam at a dose of 0.7  mg/kgbw 
together with omeprazole at a dose of 1.4mg/kgbw. The differences dose of the piroxicam and 
omeprazole based on the body weight of the rabbit. 
Blood sampling in all three treatments was carried out by: test animals blood drawn from rabbit 
marginal veins as much as 1-2 ml with a span of 0 hours; 0.5 hour; 1 hour; 1.5 hours; 2 hours; 4 
hours; 6 hours; 8 hours. The blood that has been taken is then put into a politube that has been 
given 2 drops of heparin, then vortex and centrifuged at a speed of 3000 rpm for 10 minutes, 
then add 1 ml of 20% TCA solution then centrifuged and taken supernatant. After that the levels 
were measured by using HPLC (High Performance Liquid Chromatography) by injecting 20 μl 
[9]. 
 
3.  Result and Discussion 
Based on the plasma injection at 0.5 hours to 8 hours on an HPLC device, the concentration of 
plasma  values obtained from the three treatments can be seen in Table 1. 
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Tabel 1.Value of concentration of each treatment 
Time Treatment I Treatment II Treatment III 
Animal 
test 
I II III I II III I II II 
0.5 0.5072 0.5077 0.5082 0.7241 0.7244 0.7252 0.7895 0.7897 0.7899 
1 0.8061 0.8065 0.8068 0.9682 0.9684 0.9687 1.0254 1.0256 1.0259 
1.5 0.9875 0.9877 0.9879 1.2925 1.2928 1.2930 1.5927 1.5930 1.5933 
2 1.2102 1.2105 1.2109 1.5119 1.5120 1.5124 1.6283 1.6285 1.6287 
4 0.9645 0.9647 0.9651 1.1781 1.1782 1.1787 1.3245 1.3248 1.3249 
6 0.6031 0.6033 0.6038 0.7434 0.7436 0.7440 0.9721 0.9724 0.9728 
8 0.2875 0.2877 0.2881 0.4363 0.4365 0.4367 0.6211 0.6215 0.6219 
 
 
Figure 1.Concentration Curves in Treatment I, II, III 
From the results of the injection obtained levels from each treatment are then used to determine 
the value of the pharmacokinetic parameters. In the absorption rate or ka has increased from 
1.7225 hours
-1
 in treatment I to 2.77445 hours
-1
 in treatment II and 3.0569 hours
-1
 in treatment 
III. From the value of ka obtained there is a difference but it is not significant from the three test 
groups so that it shows that the value of the three treatments does not affect the value of the 
absorption rate, the Tmax value increased from 0.9408 hours in treatment I to 1.43 hours in 
treatment II and decreased 1 3249 hours in treatment III, the Cmax value increased from 1.2558 
in treatment I 1.3603 in treatment II and 1.3901 in treatment III. 
 
In the Mirakel study, it has been explained that the increase in the value of ka influences the 
decreasing Tmax value and also influences the increase in the profile value of AUC0-∞ ie the 
data from this study is 6.43985 µg / L. Hours in treatment I to 8.1497 µg / L hours for treatment 
II and 9.0226 µg / L  hours for treatment III. Factors that can affect the absorption profile are 
gastric emptying speed, pH of the absorption medium, fat-water partition coefficient and the 
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In the distribution profile, the three treatments did not show a significant change and also the 
effect on Vd, namely the volume distribution value or Vd increased from 3.1349 L in treatment 
I to 3.7625 in treatment II and 3.7933 in treatment III. The AUMC0-nilai value which shows the 
initial concentration under the curve has increased significantly in line with the AUC0-∞ value, 
from 26,204 in treatment I to 36,2284 in treatment II and treatment III 38,0502. Factors that can 
affect the distribution profile values such as the bond between the drug and blood protein, the 
binding of the drug with tissue and partitions in fat and are not influenced by the administration 
of one or a combination of drugs so that the distribution profile value is not affected.  
 
In the elimination profile obtained from the value of elimination speed or kel which decreased 
but not significantly from treatment I that is 0.5979 hours-1 to 0.4883 hours-1 in treatment II 
and then decreased to 0.4718 hours-1 in treatment III and also in line with the Cl value of the 
three treatments which decreased from 1.8744 L / hr in treatment I to 1.8375 L / hr in treatment 
II and 1.7886 L / hr in treatment III. Cl value describes the amount of drug that is cleansed and 
is a primary pharmacokinetic parameter so that physiological factors affect the change in value. 
It is seen that treatments II and III cause a decrease in Cl value which means there is a suspicion 
that the decrease in Cl occurs due to decreased metabolism by the liver and / or excretion by the 
kidneys. And the MRT value is the value that indicates the time the presence of drugs in the 
body has increased from 4.0690 in treatment I to 4.4453 in treatment II and decreased to 4.2172 
in treatment III (Table 2). However, the three treatments showed no significant difference in 
value so it did not show the effect of the three treatments on drug elimination.From the data that 
has been obtained from each pharmacokinetic profile, there is no significant difference in the 
value of each treatment. So this shows that each treatment did not have a significant effect on 
the pharmacokinetic profile of the three treatments. 
 
Table 2. Pharmacokinetic Parameter Values of the three Treatments   
NO Pharmacokinetic 
Parameter 
Treatment I Treatment II Treatment  III 
1 Ka 1.7225 2.7445 3.0569 
2 Kel 0.5979 0.4883 0.4718 
3 T1/2 1.159 1.419 1.4688 
4 Vd 3.1349 3.7625 3.7933 
5 Cl 1.8744 1.8375 1.7886 
6 Tmax 0.9408 1.43 1.3249 
7 Cmax 1.2558 1.3603 1.3901 
8 AUC 0-∞ 6.43985 8.1497 9.0226 
9 AUMC 0-∞ 26.204 36.2284 38.0502 
10 MRT 4.0690 4.4453 4.2172 
 
T count values obtained from concentrations of 10, 14 and 18 ppm respectively were 0.2239, 
0.3198 and 0.2562 (Table 3). After obtaining the calculated t value it will be compared with the 
t table value. The t table value uses α  = 0.05, then  α / 2 = 0.05 / 2 = 0.025 and the value of n = 
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3, then n-1 = 3-1 = 2. Then the value of t table is 4.30265. The calculated t value obtained from 
each concentration is smaller than the t table value. Then it can be concluded that H0 is accepted 
or it can be said that the average compared is the same or there is no significant difference. 
Table 3.T calculated values and T tables 
Concentration  T Calculated T Tables 
10 ppm 0,2239  
4,30265 14 ppm 0,3198 
18 ppm 0,2562 
 
4. Conclusion 
Based on the research that has been done, it can be concluded that the administration of 
omeprazole affects the inhibition of the enzyme metabolizing from piroxicam and also affects 
the pharmacokinetic parameters in the absorption phase and also excretion but not significantly. 
The piroxicam treatment group that was given 1 hour before omeprazole and the piroxicam 
treatment group was given together with omeprazole showed no significant effect on 
pharmacokinetic parameters. 
Acknowledgment 
The authors thanks to Faculty of Pharmacy, Institut Kesehatan Deli Husada Deli Tua for 
supporting this research. 
 
REFERENCES 
[1] Sumarno, “Interaksi Simetidin Terhadap Kinetika Eliminasi Parasetamol pada 
Kelinci,JurnalFarmasi Indonesia, vol.3, no.1, pp.9-12. 2006. 
[2] B. D. Snyder, T. M. Polasek, and M. P. Doogue,“Drug Interactions Princeples and 
Practice,” Australian Prescriber, vol. 35, no. 3, pp. 85–88, June. 2012. 
[3] F. Rahmawati, R. Handayani, and V. Gosal, “Kajian Retrospektif Interaksi Obat di 
Rumah Sakit Pendidikan Dr. Sardjito Yogyakarta,”Majalah Farmasi Indonesia, vol. 17, 
no.4, pp. 177-183. 2006. 
[4] M. Pirmohamed, S. James, S.Meakin, C. Green, A.K. Scott, T.J. Walley, et al,” Adverse 
drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients,” 
BMJ, vol. 329, pp 15-19. 2004. 
[5] Aslam, M., Kaw Tan, C., and Prayitno, A.,” Farmasi Klinis (Clinical Pharmacy) Menuju 
Pengobatan Rasional dan Penghargaan Pilihan Pasien,” Jakarta: PT. Elex Media 
Komputindo. 2003. 
[6] Forceia, MA.,et al.,”Geriatric Secrets, Third Edition,” United States: Independence 
Square West. 2004. 
[7] Hakim, L.,”Farmakokinetik Klinik,”Yogyakarta: Bursa Ilmu. 2012. 
[8] Siswandono dan Soekardjo, B.,” Kimia Medisinal Edisi 2,” Surabaya: Airlangga 
University Press. 2000. 
[9] Iersa, R., “Pengaruh Vitamin C pada Profil Farmakokinetika Natrium Diklofenak 
Terhadap Hewan Uji Kelinci,”M.S. Thesis Universitas Sumatera Utara. Medan. 2012. 
[10] Mirakel Agatha Devi,“Pengaruh Pemberian Air Berkarbonasi Terhadap Profil 
Farmakokinetika Parasetamol Pada Tikus Putih Jantan,” M.S. Thesis Universitas Sanata 
Dharma. Yogyakarta. 2007.  
